# A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution

> **NCT04908436** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 33 (actual)

## Conditions studied

- Worsening Chronic Heart Failure
- Chronic Kidney Disease

## Interventions

- **DRUG:** Finerenone (BAY94-8862)

## Key facts

- **NCT ID:** NCT04908436
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-27
- **Primary completion:** 2011-05-05
- **Final completion:** 2012-01-27
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2022-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04908436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04908436, "A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04908436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*